Wuhan Guanggu VCANBIO Pharmaceutical

Wuhan Guanggu Vcanbio Pharmaceutical is a wholly-owned subsidiary of Vcanbio Cell & Gene Engineering Corp., Ltd., a leading Chinese biotechnology company specializing in cell and gene therapy. Based in Wuhan's Optics Valley, the company focuses on the research and development of mesenchymal stem cell (MSC) therapies derived from human umbilical cords. Its primary pipeline candidates, VUM02 and VUM03, are being evaluated for a wide range of inflammatory and autoimmune conditions, including acute graft-versus-host disease, Crohn's disease, and respiratory distress syndromes. Vcanbio leverages its parent company's extensive network in stem cell storage and precision medicine to advance its clinical programs.